Amends the Federal Food, Drug, and Cosmetic Act to prohibit a holder of a new, approved drug application from manufacturing, marketing, selling, or distributing a generic version of such drug during any exclusivity period granted to manufacturers of generic brands.
Referred to the Subcommittee on Health.
Introduced in Senate
Sponsor introductory remarks on measure. (CR S7927)
Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text of measure as introduced: CR S7928)
checking server…
Ask anything about this bill. The AI reads the full text to answer.
Enter to send · Shift+Enter for new line